for Clonazepam and 181 for Fluoxetine and Imipramine. The incremental cost-effectiveness analysis showed that the cost of an extra unit of effectiveness was $32.2 when changing from Alprazolam to Clonazepam, while the two other alternatives (Fluoxetine and Imipramine) were dominated. Sensitivity analysis confirmed the direction and strength of our results. Confidence interval at 95% of the ICER was calculated by the ellipse method and it showed that Alprazolam was dominant in 87% of the cases. Acceptability curve described Alprazolam as the best option with a willingness to pay threshold of $32.2. CONCLU-SIONS: The best cost-effective alternative was Alprazolam followed by Clonazepam. This results are relevant for the IMSS because anxiety disorders cause work leaves and hospitalisations, and reduction in quality of life.
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PMH5 ECONOMIC BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) AND OTHER ANXIETY DISORDERS
Chang S 1 , Mark TL 1 , Brandenburg N 2 1 Medstat, Washington, DC, USA; 2 Pfizer, Inc, New York, NY, USA OBJECTIVES: To assess the health and cost burdens of patients with generalized anxiety disorder (GAD) and other anxiety disorders, including their comorbidities, direct and indirect costs. METHODS: The 1999-2003 MarketScan ® claims databases of over three million individuals (annually) were used to identify patients with a diagnosis of GAD, other anxiety disorders (panic disorder, phobias, post traumatic stress disorder, unspecified anxiety state), and demographically-matched controls. Presence of comorbidities, utilization, expenditures, absence and shortterm disability (STD) were summarized over a 12-month study period. RESULTS: The prevalence of the following conditions were significantly (p < 0.001) higher among the 13,836 GAD subjects and 31,882 other anxiety patients compared to the 89,971 controls: gastrointestinal disorders (19% GAD, 22% other anxiety, 12% controls), genitourinary disorders (40% GAD and other anxiety, 32% controls), cardiovascular disease (10% GAD, 11% other anxiety, 7% controls), and chronic pain (40% GAD, 44% other anxiety, 20% controls). Mean costs for anxiety patients were twice as high as for controls ($6295 GAD, $6800 other anxiety, $3156 controls, p < 0.001). These differences were driven by significantly higher rates of office visits and prescription drug use among anxiety patients. Mental health costs for GAD patients ($2031) or other anxiety patients ($2005) did not account for all of the discrepancy. Among the subset of patients with productivity data, anxiety patients had significantly higher indirect costs due to STD days ($2253 GAD, $3255 other anxiety, $934 controls, p < 0.001). CONCLUSION: Patients with GAD and other anxiety disorders have significantly higher costs compared to patients without these conditions. The direct and indirect costs of anxiety result from mental health treatment and treatments for physical comorbidities. stay of three or more months. Independent variables were measured at the baseline and included age, gender, race, education, marital status, living arrangements, income, homeownership, Medicaid, physical function (ADL/IADL), cognitive level, perceived health status and certain chronic illnesses such as stroke, psychiatric problems, fall and incontinence. RESULTS: In the final multivariable Cox model, older age (Hazard Ratio [HR], 1.11; 95% CI, 1.09-1.24), persons with psychiatric problems (HR, 1.49; 95% CI, 1.19-1.87) and worse health were found to increase the risk of permanent nursing home admission whereas being African American compared to white (HR, 0.85; 95% CI, 0.56-0.95) and persons with less cognitive impairment (HR, 0.95; 95% CI, 0.91-0.99) had decreased risk. The interaction terms between time and living alone and IADL were significant and less than one, which means the negative impacts of living alone and worse IADL were decreasing over time. Gender, education, marital status, income, homeownership, Medicaid, ADL, stroke, fall and incontinence were not significant. CONCLUSION: Older age, psychiatric problems and worse perceived health are the risk factors for permanent nursing home admission. Living alone and worse IADL also increase the risk of nursing home admission, however, the negative impacts appear to ameliorate over time. The differential effects of ADL and IADL on nursing home admission warrant more future research.
PMH7 THE EFFECT OF VENLAFAXINE, PAROXETINE, AND PLACEBO ON HEALTH-RELATED WORK PRODUCTIVITY IN PANIC DISORDER PATIENTS
Khandker R, Zhang HF Wyeth Research, Collegeville, PA, USA OBJECTIVES: This study assessed the effect of treatment with venlafaxine extended release (XR), paroxetine and placebo on health related work productivity among panic disorder patients. METHODS: In a multicenter, double-blind trial, patients with DSM-IV panic disorder were randomly assigned to fixed-dose (75 mg/day or 225 mg/day) venlafaxine XR, paroxetine (40 mg/day), or placebo for a maximum of 12-weeks. Secondary analyses focused on health-related work productivity impairments as measured by the Work Limitations Questionnaire (WLQ). WLQ has 25 items in four limitation dimensions (time, physical, mental-interpersonal, and output demands). Treatment-related improvements at final-on-therapy (FOT) and week 12 were compared using analysis of covariance adjusting for baseline impairment score and center. RESULTS: Venlafaxine XR 225 mg was associated with significantly greater improvement from baseline, relative to placebo, on all subscales of WLQ (P < 0.005) except physical demands. At the FOT assessment, venlafaxine XR 75 mg showed significant improvement compared with placebo in time management (P < 0.05), marginally significant improvement in mental/interpersonal demands (P = 0.059) and output demands (P = 0.054), and no significance for physical demands. Paroxetine failed to show significant improvement relative to placebo on all WLQ subscales in the FOT assessment. CONCLUSION: Venlafaxine reduced work impairment compared to placebo. Paroxetine did not separate from placebo.
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